RxDoctor Payments Data

Sushanth Kakarla

Internal Medicine · San Antonio, TXNPI 1710338173

Payments from drug & device makers

$7,237in general payments, 2019–2025

Across 277 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • E.r. Squibb & Sons, L.L.C.$727
  • Novartis$444
  • Merck$336
  • Janssen Scientific Affairs, LLC$319
  • Amgen$307
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$6,93496%
  • Education$3034%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,237 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$100,121
Medicare patients
261
Services billed
1,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate36$561,124
PromactaEltrombopag Olamine22$201,583
CalquenceAcalabrutinib Maleate12$172,621
EliquisApixaban45$36,633
Anastrozole134$4,029
Abiraterone Acetate14$3,029
Fentanyl21$2,023
Tamoxifen Citrate59$1,676
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19$1,279
Levothyroxine Sodium42$995
Potassium Chloride38$975
Prochlorperazine Maleate69$970
Ondansetron OdtOndansetron37$836
Letrozole20$694
Dexamethasone34$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali, Promacta$444$762,70758 claims
AstraZenecaCalquence$1,103$172,62112 claims
PfizerEliquis$224$36,63345 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$319$3,02914 claims
Lilly USA, LLCOlanzapine$36$40534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →